Vitreo Retinal Diseases

FP1274 : Safety and Efficacy of Razumab – the New Biosimilar in India : Our Experience

Dr. Shravan Masurkar, M16534, Dr. Shrinivas M Joshi, Dr. Sameera. V. V, Dr. Apoorva A G, Dr. Guruprasad Ayachit

A prospective analysis was performed in patients with neovascular AMD (Group 1),macular oedema secondary to RVO (Group2) and DME (Group3) who received intravitreal Razumab at baseline.Snellen visual acuity,anterior and posterior segment evaluation including fundus photo and optical coherence tomography imaging was done at Day 0,1,7 and 30.